Towards small-molecule CXCR3 ligands with clinical potential.
The CXCR3 chemokine receptor was first discovered in 1996 and has been shown to play an important role in several diseases, most of which are related to inflammation. This review describes in detail the development of small CXCR3 ligands and their therapeutic potential. Classes of CXCR3 antagonists with strikingly variable core structures have emerged. Some of these compounds have confirmed the beneficial role of CXCR3 antagonism in animal models of disease. One of the compounds, AMG487, progressed to Phase II clinical trials but has been withdrawn because of lack of efficacy. New antagonist classes are being developed to reveal the full therapeutic potential of CXCR3.
Wijtmans
Maikel
M
Leiden/Amsterdam Center for Drug Research, Division of Medicinal Chemistry, Faculty of Sciences, VU University Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands. wijtmans@few.vu.nl
Verzijl
Dennis
D
Leurs
Rob
R
de Esch
Iwan J P
IJ
Smit
Martine J
MJ
D000818:Animals; D000906:Antibodies / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D008024:Ligands; D015394:Molecular Structure; D009930:Organic Chemicals / Q000737:chemistry / Q000494:pharmacology*; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology; D011506:Proteins / Q000737:chemistry / Q000494:pharmacology; D054367:Receptors, CXCR3 / Q000819:agonists* / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship
D000906:Antibodies; D008024:Ligands; D009930:Organic Chemicals; D010455:Peptides; D011506:Proteins; D054367:Receptors, CXCR3